• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Forum Markets Incorporated filed SEC Form 8-K: Other Events

    6/30/26 6:30:36 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FRMM alert in real time by email
    false 0001690080 0001690080 2026-06-29 2026-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): June 29, 2026

     

    Forum Markets, Incorporated

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38105   90-1890354
    (State or Other Jurisdiction
    of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    2875 South Ocean Blvd, Suite 100
    Palm Beach, FL
      33480
    (Address of Principal Executive Offices)   (Zip Code)

     

    (650) 507-0669

    (Registrant’s telephone number, including area code)

     

     

    (Former name or former address, if changed since last report)

      

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

      

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   FRMM   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 8.01 Other Events.

     

    On June 29, 2026, the Board of Directors (the “Board of Directors”) of Forum Markets, Incorporated (the “Company”) approved an amendment to the Company’s existing share repurchase program (the “Repurchase Program”), which was scheduled to terminate on June 30, 2026. Pursuant to the amendment, the Repurchase Program has been extended for one year, through June 30, 2027. The Board of Directors also approved expanding the program to expressly authorize the Company to effect repurchases through derivative transactions, in addition to other methods of repurchase that may be available to the Company from time to time. The Board of Directors also reduced the aggregate repurchase authorization under the Repurchase Program from $250 million to $100 million. As of June 29, 2026, the Company had 13,210,145 shares of common stock outstanding.

     

    The Board of Directors will determine the actual timing, number, and value of any shares repurchased under the Repurchase Program in its discretion using factors such as, but not limited to, stock price, trading volume, general market conditions, and the ongoing assessment of the Company’s capital needs. There is no assurance of the number or aggregate price of any shares that the Company will repurchase. The Repurchase Program may be extended, suspended, or terminated at any time by the Board of Directors.

     

    This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include all statements other than statements of historical fact, including but not limited to statements about whether or how the Company may repurchase shares under the Repurchase Program or how many shares, if any, the Company may repurchase. Additional information regarding factors that could materially affect results and the accuracy of the forward-looking statements contained herein may be found in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on April 1, 2026 and Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 15, 2026, and in our subsequent filings with the SEC.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      FORUM MARKETS, INCORPORATED
       
    Date: June 30, 2026 By: /s/ McAndrew Rudisill
        Name:  McAndrew Rudisill
        Title: Chief Executive Officer

     

    2

     

    Get the next $FRMM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FRMM

    DatePrice TargetRatingAnalyst
    4/7/2026$5.00Speculative Buy
    The Benchmark Company
    More analyst ratings

    $FRMM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on Forum Markets with a new price target

    The Benchmark Company initiated coverage of Forum Markets with a rating of Speculative Buy and set a new price target of $5.00

    4/7/26 8:46:27 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    SEC Filings

    View All

    Forum Markets Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - FORUM MARKETS Inc (0001690080) (Filer)

    7/16/26 8:00:14 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Forum Markets Incorporated

    DEFA14A - FORUM MARKETS Inc (0001690080) (Filer)

    7/9/26 4:02:18 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Forum Markets Incorporated

    DEF 14A - FORUM MARKETS Inc (0001690080) (Filer)

    7/8/26 4:11:15 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Forum Markets Acquires Aircraft Engine for Approximately $12 Million, Advances Plan to Expand Aviation Portfolio to Five Engines

    Company Expects to Complete Acquisition of an Additional Engine in the Coming Weeks; Most Widely Used Engine Platform Offers Scale and Repeatable Deal Flow PALM BEACH, Fla., July 16, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM), a digital asset platform modernizing capital markets through the tokenization of real-world assets, today announced that it has closed on the acquisition of a commercial aircraft engine for approximately $12 million in cash, expanding the company's aviation portfolio to four income-generating engines under long-term lease to major U.S. airlines. Forum is in the process of finalizing the purchase of an a

    7/16/26 8:00:00 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forum Announces Initiation of Analyst Coverage by Sidoti & Company with $10.00 Price Target

    PALM BEACH, Fla., May 29, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM), a digital asset platform modernizing capital markets through the tokenization of real-world assets, today announced that Sidoti & Company, LLC has initiated coverage of the company's common stock with a Not Rated (NR) classification and a price target of $10.00 per share. Sidoti is the third research firm to initiate coverage of Forum in 2026. The research report, authored by Brendan McCarthy, CFA, was published on May 28, 2026. Sidoti's initiation highlights Forum's position as an early mo

    5/29/26 8:00:00 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forum to Present at Benchmark's Digital Assets Summit on May 27

    PALM BEACH, Fla., May 19, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM) ("Forum"), a digital asset platform modernizing capital markets through the tokenization of real-world assets, today announced that McAndrew Rudisill, chairman and CEO, and John Kristoff, senior vice president, corporate communications and investor relations, are expected to participate in the Benchmark Digital Assets Summit on Wednesday, May 27, 2026, in New York.  The company will participate in the panel discussion "How Tokenization Is Reshaping Private and Public Markets" at 3:00 PM EDT

    5/19/26 8:00:00 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Lomashuk Konstantin sold $16,141 worth of shares (2,562 units at $6.30) (SEC Form 4)

    4 - FORUM MARKETS Inc (0001690080) (Issuer)

    7/20/26 9:26:28 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Lomashuk Konstantin sold $20,846 worth of shares (3,387 units at $6.15) (SEC Form 4)

    4 - FORUM MARKETS Inc (0001690080) (Issuer)

    7/14/26 4:25:34 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Lomashuk Konstantin sold $30,477 worth of shares (4,802 units at $6.35) (SEC Form 4)

    4 - FORUM MARKETS Inc (0001690080) (Issuer)

    7/9/26 4:44:25 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    Financials

    Live finance-specific insights

    View All

    Forum Markets Acquires Aircraft Engine for Approximately $12 Million, Advances Plan to Expand Aviation Portfolio to Five Engines

    Company Expects to Complete Acquisition of an Additional Engine in the Coming Weeks; Most Widely Used Engine Platform Offers Scale and Repeatable Deal Flow PALM BEACH, Fla., July 16, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM), a digital asset platform modernizing capital markets through the tokenization of real-world assets, today announced that it has closed on the acquisition of a commercial aircraft engine for approximately $12 million in cash, expanding the company's aviation portfolio to four income-generating engines under long-term lease to major U.S. airlines. Forum is in the process of finalizing the purchase of an a

    7/16/26 8:00:00 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forum Reports First Quarter 2026 Financial Results

    PALM BEACH, Fla., May 14, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM) ("Forum" or the "Company"), a digital asset platform modernizing capital markets through the tokenization of real-world assets, today reported financial results for the first quarter ended March 31, 2026. "Forum continues to execute against our core strategy of building a platform centered on originating, structuring, and tokenizing institutional-grade, yield-generating assets," said McAndrew Rudisill, chairman and CEO. "We've expanded our origination capabilities with our entry into AI infr

    5/14/26 8:00:00 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forum Reports Fourth Quarter and Full Year 2025 Financial Results

    Company Introduces 2026 Guidance as RWA Tokenization Platform Begins to Scale PALM BEACH, Fla., March 31, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM) ("Forum" or the "Company"), a digital asset platform modernizing capital markets through the tokenization of real-world assets on Ethereum, today reported financial results for the fourth quarter and full year ended December 31, 2025. "In less than a year, Forum has moved from concept to execution: from building the infrastructure, establishing key partnerships, and validating our technology, to generating revenu

    3/31/26 9:00:00 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    Leadership Updates

    Live Leadership Updates

    View All

    Forum Appoints Robert Spake as General Counsel

    PALM BEACH, Fla., March 3, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM), a digital asset platform modernizing capital markets through the tokenization of real-world assets on Ethereum, today announced the appointment of Robert Spake as the company's general counsel. Spake's deep legal expertise in capital markets, tokenization, and regulatory compliance strengthens Forum's leadership team and sharpens its focus on launching compliant, institutionally structured real-world asset products within evolving regulatory frameworks.  "Robert joins Forum at a pivotal mo

    3/3/26 9:00:00 AM ET
    $ETHZ
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care